Purpose: Current guidelines recommend vaccination at least 2 weeks before chemotherapy initiation to optimize the immune response despite limited evidence. Our previous study indicated no differences in short-term immune response for the 13-valent pneumococcal conjugate vaccine (PCV13) according to the vaccination timing. This study aims to investigate the long-term efficacy of PCV13 and clinical factors associated with the respective antibody response. Materials and Methods: Patients with gastric or colorectal cancer who received adjuvant chemotherapy were enrolled and divided into two groups: vaccinated 2 weeks before chemotherapy (arm A) and vaccinated concurrently with chemotherapy (arm B). Serum samples were collected before vaccination and in one month, 3 years, and 5 years. Immune responses were measured using enzyme-linked immunosorbent assay and multiplex opsonophagocytosis assay. Results: Including 63 patients, both groups showed an initial increase in the geometric mean titers of opsonophagocytic activity and the geometric mean concentrations of serotype-specific IgG levels after one month, followed by a decline at 3 and 5 years, particularly for serotypes 1, 14, 18C, and 19A. Despite the decline, global protection was maintained for 5 years, although global response decreased. The two arms did not show significant differences in immunogenicity nor in factors such as vaccination timing, age, cancer type, or chemotherapy regimen. Conclusion Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for > 5 years, and global response remained in over half of patients.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

Objective: Adenomyosis impacts pregnancy outcomes, although there is a lack of consensus regarding the actual effects. It is likely, however, that the severity of adenomyosis or ultrasound findings or timing of diagnosis can have different effects on adverse pregnancy outcomes (APOs). Methods: In this study, we aimed to investigate the impact of the timing of adenomyosis diagnosis on pregnancy outcomes. Singleton pregnant women who delivered between 2017 and 2022 were analyzed based on the timing of adenomyosis diagnosis, using a national database. The final cohort was classified into three groups: 1) group 1, without adenomyosis; 2) group 2, those diagnosed with adenomyosis before pregnancy; and 3) group 3, those diagnosed with adenomyosis during pregnancy. Results: A total of 1,226,475 cases were ultimately included in this study. Women with a diagnosis of adenomyosis had a significantly higher risk of APOs including hypertensive disorder during pregnancy (HDP), gestational diabetes mellitus (GDM), postpartum hemorrhage, placental abruption, preterm birth, and delivery of a small-for-gestational-age infant even after adjusting for covariates. In particular, concerning HDP, the risk was highest in group 3 (group 2: adjusted odds ratio [aOR], 1.15 vs. group 3: aOR, 1.36). However, the highest GDM risk was in group 2 (GDM; group 2: aOR, 1.24 vs. group 3: aOR, 1.04). Conclusion The increased risk of APO differed depending on the timing of adenomyosis diagnosis. Therefore, efforts for more careful monitoring and prevention of APOs may be necessary when such women become pregnant.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.